These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. DeJesus E; Herrera G; Teofilo E; Gerstoft J; Buendia CB; Brand JD; Brothers CH; Hernandez J; Castillo SA; Bonny T; Lanier ER; Scott TR; Clin Infect Dis; 2004 Oct; 39(7):1038-46. PubMed ID: 15472858 [TBL] [Abstract][Full Text] [Related]
25. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E; Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872 [TBL] [Abstract][Full Text] [Related]
26. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. ; Carey D; Puls R; Amin J; Losso M; Phanupak P; Foulkes S; Mohapi L; Crabtree-Ramirez B; Jessen H; Kumar S; Winston A; Lee MP; Belloso W; Cooper DA; Emery S Lancet Infect Dis; 2015 Jul; 15(7):793-802. PubMed ID: 25877963 [TBL] [Abstract][Full Text] [Related]
28. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. Fisher M; Moyle GJ; Shahmanesh M; Orkin C; Kingston M; Wilkins E; Ewan J; Liu H; Ebrahimi R; Reilly G; J Acquir Immune Defic Syndr; 2009 Aug; 51(5):562-8. PubMed ID: 19561519 [TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States. Brogan AJ; Talbird SE; Cohen C Value Health; 2011; 14(5):657-64. PubMed ID: 21839403 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. Lockman S; Brummel SS; Ziemba L; Stranix-Chibanda L; McCarthy K; Coletti A; Jean-Philippe P; Johnston B; Krotje C; Fairlie L; Hoffman RM; Sax PE; Moyo S; Chakhtoura N; Stringer JS; Masheto G; Korutaro V; Cassim H; Mmbaga BT; João E; Hanley S; Purdue L; Holmes LB; Momper JD; Shapiro RL; Thoofer NK; Rooney JF; Frenkel LM; Amico KR; Chinula L; Currier J; Lancet; 2021 Apr; 397(10281):1276-1292. PubMed ID: 33812487 [TBL] [Abstract][Full Text] [Related]
31. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults. Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE; HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008 [TBL] [Abstract][Full Text] [Related]
32. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K; Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123 [TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine. Vourvahis M; Davis J; Langdon G; Layton G; Fang J; Choo HW; Hansson AG; Tawadrous M Antivir Ther; 2013; 18(6):745-54. PubMed ID: 23558061 [TBL] [Abstract][Full Text] [Related]
34. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934. Margot NA; Enejosa J; Cheng AK; Miller MD; McColl DJ; J Acquir Immune Defic Syndr; 2009 Oct; 52(2):209-21. PubMed ID: 19644384 [TBL] [Abstract][Full Text] [Related]
35. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection. Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316 [TBL] [Abstract][Full Text] [Related]
36. WITHDRAWN: Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV. Omeje I; Okwundu CI Cochrane Database Syst Rev; 2012 May; 2012(5):CD007276. PubMed ID: 22592718 [TBL] [Abstract][Full Text] [Related]
37. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. Cohen C; Wohl D; Arribas JR; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Ebrahimi R; Porter D; White K; Walker I; Chuck S; De-Oertel S; Fralich T AIDS; 2014 Apr; 28(7):989-97. PubMed ID: 24508782 [TBL] [Abstract][Full Text] [Related]